Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Relapsed/Refractory Multiple Myeloma · Relapsed/Refractory Autoimmune Diseases

Nanjing Legend Biotech

Nanjing Legend Biotech Co.

Nanjing Legend Biotech patent portfolio — 26 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
2101 Cottontail Lane, Somerset, New Jersey 08873, US HQ
2,457 Employees
NMPA registrant Type
Company details
Status
Public
HQ
2101 Cottontail Lane, Somerset, New Jersey 08873, US
Employees
2,457
Programs
36
Drugs
17
Patents
26
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Nanjing Legend Biotech patents

26 pharmaceutical patents indexed for Nanjing Legend Biotech. 0 expire within 24 months.

Nanjing Legend Biotech has 26 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

26 patents

Patent portfolio

  1. US 12421292

    Anti-DLL3 chimeric antigen receptors and uses thereof

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12351638

    Chimeric antigen receptors targeting BCMA and methods of use thereof

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12275788

    Single-domain antibodies against CD33 and constructs thereof

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12258418

    Claudin18.2 binding moieties and uses thereof

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12240914

    Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12168688

    Antibodies and variants thereof against PD-L1

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12097219

    Single-domain antibodies against CLL1 and constructs thereof

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12006363

    Anti-tetraspanin 33 agents and compositions and methods for making and using the same

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11958903

    Single-domain antibodies against LAG-3 and uses thereof

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11932698

    Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11905327

    Single-domain antibodies and variants thereof against TIGIT

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11827713

    Chimeric antibody immune effector cell engagers and methods of use thereof

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11713353

    Single-domain antibodies and variants thereof against PD-1

    Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11708410

    Antibodies and variants thereof against TIGIT

    Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11673954

    Single-domain antibodies and variants thereof against PD-L1

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11608489

    Compositions and methods for performing magnetibuoyant separations

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11564945

    Chimeric antigen receptor and use thereof

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11535677

    Chimeric antigen receptors targeting BCMA and methods of use thereof

    Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11505601

    Compositions and methods using a single-domain antibody binding transferrin and protein A for increasing protein half-life in serum

    Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11472881

    Single-domain antibodies and variants thereof against CTLA-4

    Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11447573

    Multispecific antigen binding proteins and methods of use thereof

    Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11401317

    Human-CD123-targeting chimeric receptor ligand and application thereof

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11186647

    Chimeric antigen receptors targeting BCMA and methods of use thereof

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11168146

    Compositions and methods for increasing protein half-life in a serum

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10934363

    Chimeric antigen receptors based on single domain antibodies and methods of use thereof

    Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10407508

    Compositions and methods for increasing protein half-life in a serum

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Nanjing Legend Biotech have?

26 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Nanjing Legend Biotech patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.